Macrophage-specific PHGDH protects against MAFLD by suppressing TAK1
Summary: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a progressive disease with only one approved treatment currently available. Hepatic phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme of the serine biosynthesis pathway, regulates MAFLD development. However, the...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2025-03-01
|
| Seri Bilgileri: | Cell Reports |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2211124725001974 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|